Filed with ASX · · 12 pages · English
Avecho Biotechnology Limited announces that CEO Dr. Paul Gavin will present at the Canaccord Drug and Device Conference, providing updates on the company's Phase III CBD insomnia trial, which has successfully passed an interim analysis. This announcement serves to inform stakeholders about the company's progress and future plans in the clinical development of its CBD product.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168avecho.com.au ASX Announcement13 October 2026Avecho to present at the Canaccord Drug and Device ConferenceMelbourne, Australia, 13 October...
Avecho Biotechnology Limited on 6ix
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology